The Top 5 Biosimilars Articles for the Week of September 17

The Center for Biosimilars® recaps the top news for the week of September 17, 2018.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 17.

Number 5: Chinese researchers are reporting positive preclinical results for a proposed cetuximab biosimilar.

Number 4: Mylan and Fujifilm have revealed that they will launch their adalimumab biosimilar in the European Union on or after October 16.

Number 3: The European Medicines Agency has published new materials intended to educate European patients about biosimilars.

Number 2: The Senate has passed a bill that would eliminate pharmacy gag clauses and require biosimilar and biologics developers to report patent settlements to the Federal Trade Commission.

Number 1: The State of California is suing AbbVie for allegedly using kickbacks and a network of nurses to illegally boost sales of Humira.

Finally, last week, our e-newsletter asked whether you think that interchangeability is the appropriate benchmark for pharmacy-level substitution.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.